Clinical Trial

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Study acronym: BONAPH1DE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Protocol Amendment History 47 amendments
This ClinicalTrials.gov record has been amended 47 times since 2021-07-20; most recent amendment 2026-04-23.
Status change: Recruiting → Active, Not Recruiting 2025-12-18
Status change: Not Yet Recruiting → Recruiting 2021-11-09
Trial Details
NCT Number NCT04982393
Lead Sponsor Alnylam Pharmaceuticals
Conditions Primary Hyperoxaluria Type 1
Enrollment 207 participants
Start Date 2021-12-13
Primary Completion 2028-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-24